Ophthotech Could Receive $1B+ in Novartis Eye Drug Agreement

May 20, 2014


According to a Reuters article, Ophthotech Corp. could potentially receive more than $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. The company said that a unit of Novartis will market its lead experimental eye drug, Fovista, outside the United States.

Ophthotech said it could receive immediate and near-term milestone payments of up to $330 million and is eligible to get ex-US marketing approval and sales milestone payments of up to $700 million. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments